EDGEWISE THERAPEUTICS INC
A biopharmaceutical company focused on developing treatments for rare musculoskeletal diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Edgewise Therapeutics' stock with a target price of $44.88, indicating strong growth potential.
Financial Health
Edgewise Therapeutics is showing strong financial performance with good cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EWTX
Gene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline growth potential
Edgewise’s valuation is closely tied to clinical data; positive trial readouts could change outlook, though biotech results are uncertain and can disappoint.
Rare disease focus
Targeting rare and genetically defined muscle disorders can offer clearer regulatory paths and distinct patient needs, yet market size and reimbursement remain considerations.
Upcoming clinical catalysts
Near‑term study readouts and regulatory interactions may act as catalysts, while financing and safety outcomes are additional variables to watch.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
